)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ajanta Pharma
Ajanta Pharma (AJANTPHARM) investor relations material
Ajanta Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary30 Oct, 2026
Executive summary
Q2 revenue from operations rose 33% YoY to ₹1,794 crore; PAT increased 49% to ₹388 crore, and adjusted EBITDA excluding forex loss rose 47% to ₹543 crore.
H1 revenue from operations grew 29% to ₹3,420 crore; PAT rose 40% to ₹722 crore and adjusted EBITDA excluding forex loss increased 34% to ₹997 crore.
Branded generics accounted for 66% of sales in Q2 and H1; US generics also delivered strong growth in both periods.
Financial highlights
Q2 gross profit rose 36% to ₹1,409 crore; gross margin was 79%, versus 77% in Q2 FY26.
Q2 reported EBITDA was ₹543 crore, up 66% YoY; adjusted EBITDA excluding forex MTM was ₹543 crore, up 47%, at a 30% margin.
H1 reported EBITDA was ₹971 crore, up 43%, at a 28% margin; adjusted EBITDA excluding ₹26 crore of forex loss was ₹997 crore, up 34%, at a 29% margin.
H1 gross profit grew 31% to ₹2,707 crore at a 79% margin; PAT margin was 21% in H1 and 22% in Q2.
Outlook and guidance
FY27 consolidated revenue growth guidance remains high teens; regional guidance is high single digits for US generics, mid-teens for Asia and India, and high double digits for Africa branded generics.
FY27 gross margin is guided at ~78% ±100 bps and EBITDA margin at ~27% ±100 bps; lower H2 margins are expected as US and institutional sales normalize and investment rises.
FY27 R&D guidance is ~5% of revenue, tax rate ~26.5%, and capex ~₹400 crore.
H2 growth is expected to remain robust but may be slightly below H1 momentum.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ajanta Pharma
- African institutional contraction cut revenue, while India and US growth cushioned the decline.AJANTPHARM
Q4 18/19 - US generics and diversified branded growth lifted FY20 revenue 26%.AJANTPHARMQ4 19/20
- Revenue rose 12% and PAT 40% as diversified pharma markets powered through COVID-19.AJANTPHARMQ4 20/21
- Branded Generics drove 16% revenue growth as normalized spending and segment headwinds pressured margins.AJANTPHARMQ4 21/22
- Revenue grew 6%, but new-plant costs and R&D pressure cut FY18 profit 8%.AJANTPHARMQ4 17/18
- FY17 profit rose 22% as U.S. launches and India growth offset emerging-market weakness.AJANTPHARMQ4 16/17
- Formulation-led exports and R&D gains offset bulk-plant exit costs.AJANTPHARMQ4 99/00
- FY14 revenue rose 30%, PAT more than doubled and EBITDA margin reached 31%.AJANTPHARMQ4 13/14
- FY15 revenue rose 23%, PAT 32%, and EBITDA margin reached 34%.AJANTPHARMQ4 14/15
Next Ajanta Pharma earnings date
Q3 26/2729 Jan, 2027
Ajanta Pharma
Next Ajanta Pharma earnings date
Q3 26/2729 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ajanta Pharma Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and branded pharmaceutical formulations. The company focuses on therapeutic segments such as ophthalmology, dermatology, cardiology, and pain management. Ajanta Pharma serves domestic and international markets, supplying products across regulated and emerging markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.